Some common clinical symptoms of BA.4 and BA.5 infected persons, such as fatigue, cough, fever, headache, etc., all increased, and the symptoms lasted for seven days. A British study found that loss of smell and taste is no longer the most "indicator" symptom of the COVID-19 outbreak, while the first symptom of the infection was a "sore throat". Sore throats are currently the leading symptom of confirmed cases, with about 58% reporting such symptoms, according to data from 17,500 people diagnosed this week by ZOE Health Research, which tracks the outbreak in the UK.
The other top ten symptoms job email list were headache (49%), cough without phlegm (40%), runny nose (40%), cough with phlegm (37%), hoarseness (35%), sneezing (32%) %), fatigue (27%), muscle pain (25%), dizziness (18%). According to the epidemic in the United States, the White House epidemiologist Dr. Anthony Fauci called: "We must take BA.5 seriously, it can really 100% escape the resistance generated by the previous infection. Compared with the previous variant, BA. .5 has an overwhelming dissemination advantage.” What does the Omicron BA.5 do? What does the Omicron BA.5 do? Let's take a look:
Japanese study: A Kyoto University study found that Omicron BA.5 is at least 1.3 times more transmissible than previously circulating BA2 subtype strains. Another analysis by Japan's National Institute of Infectious Diseases put the figure at 1.4 times. In addition, another study by Kyoto University also found that the third dose of Pfizer vaccine was only 48.5% effective in preventing infection with BA.5 two weeks after inoculation. Experts believe this ratio shows the "limited effect" of supplements. BA.5 has the function of evading immunity, and the vaccine prevention effect of BA.5 is 4 times lower than that of BA.2. 2. South African study: People who have been infected with COVID-19 have an increased rate of secondary diagnoses. 11.5% of the BA.1 cases had a history of previous infection, and 18.9% of the BA.4 and BA.5 cases, which was much higher than the proportion of the previous mutant cases whose history of infection was less than 3%.